BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: A case report

British Journal of Dermatology

Volumn 168, Issue 2, 2013, Pages 428-430

  Richtig, E ^a   Schrama, D ^a   Ugurel, S ^a   Fried, I ^a   Niederkorn, A ^a   Massone, C ^a   Becker, J C ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DACARBAZINE;

AGED; BACK; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; FEMALE; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LETTER; MELANOMA; PRIORITY JOURNAL; SATELLITE METASTASIS; SENTINEL LYMPH NODE BIOPSY; TREATMENT DURATION; TUMOR VOLUME;

AGED; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FATAL OUTCOME; FEMALE; HUMANS; LYMPHATIC METASTASIS; MELANOMA; MUTATION; NEOPLASMS, SECOND PRIMARY; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; TIME-TO-TREATMENT;

EID: 84873173578     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11121.x     Document Type: Letter

References (13)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
2. Long GV, Menzies AM, Nagrial A, et al. Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma. J Clin Oncol 2010; 28:15S (suppl.; abstr. 8548) presented at the ASCO Annual Meeting, 4-8 June 2010, Chicago, IL, U.S.A.
3. Jakob JA, Bassett RL, Ng CS, et al. Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. J Clin Oncol 2011; 29 (suppl.; abstr. 8500) presented at the ASCO Annual Meeting, 3-7 June 2011, Chicago, IL, U.S.A.
4. Dienstmann R, Tabernero J,. BRAF as a target for cancer therapy. Anticancer Agents Med Chem 2011; 11: 285-95.
5. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
6. U.S. Food and Drug Administration News Release. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm268241.htm (last accessed 2 July 2012).
7. Infante JR, Falchook GS, Lawrence DP, et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK 1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK 2118436 (GSK 436). J Clin Oncol 2011; 29 (suppl.; abstr. CRA8503) presented at the ASCO Annual Meeting, 3-7 June 2011, Chicago, IL, U.S.A.
8. Benlloch S, Paya A, Alenda C, et al. Detection of BRAF V600E mutation in colorectal cancer. Comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn 2006; 8: 540-3.
9. Pichler M, Balic M, Stadelmeyer E, et al. Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn 2009; 11: 140-7.
10. Carbonell P, Turpin MC, Torres-Moreno D, et al. Comparison of allelic discrimination by dHPLC, HRM, and TaqMan in the detection of BRAF mutation V600E. J Mol Diagn 2011; 13: 467-73.
11. Fusi A, Berdel R, Havemann S, et al. Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity. Eur J Cancer 2011; 47: 1971-6.
12. Houben R, Becker JC, Kappel A, et al. Constitutive activation of the Ras-Raf signalling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004; 3: 6.
13. Yancovitz M, Litterman A, Yoon J, et al. Intra- and inter-tumor heterogeneity of BRAF (V600E) mutations in primary and metastatic melanoma. PLoS ONE 2012; 7: e29336.